10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells.

Our studies showed that an abundant folate enzyme, 10-formyltetrahydrofolatedehydrogenase (FDH), is strongly down-regulated in several types of cancer on both the mRNA and the protein level. Transient expression of FDH in several human prostate cancer cell lines, a hepatocarcinoma cell line, HepG2, and a lung cancer cell line, A549, suppressed proliferation and resulted in cytotoxicity. In contrast, overexpression of a catalytically inactive FDH mutant did not inhibit proliferation, which suggests that the suppressor effect of FDH is a result of its enzymatic function. Because the FDH substrate, 10-formyltetrahydrofolate, is required for de novo purine biosynthesis, we hypothesized that the inhibitory effects of FDH occur through the depletion of intracellular 10-formyltetrahydrofolate followed by the loss of de novo purine biosynthesis. The ultimate impact is diminished DNA/RNA biosynthesis. Indeed, supplementation of FDH-overexpressing cells with 5-formyltetrahydrofolate or hypoxanthine reversed the FDH growth-inhibitory effects. Hence, down-regulation of FDH in tumors is proposed to be one of the cellular mechanisms that enhance proliferation.

[1]  Simon C Watkins,et al.  Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver , 2001, Hepatology.

[2]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[3]  C. Wagner.  BIOCHEMICAL ROLE OF FOLATE IN CELLULAR METABOLISM* , 2001 .

[4]  L. Kluijtmans,et al.  The human and mouse methylenetetrahydrofolate reductase (MTHFR) genes: genomic organization, mRNA structure and linkage to the CLCN6 gene. , 2000, Gene.

[5]  L. Bailey,et al.  Folate metabolism and requirements. , 1999, The Journal of nutrition.

[6]  M. Rhee,et al.  Glutamyl hydrolase: properties and pharmacologic impact. , 1999, Seminars in oncology.

[7]  H. Calvert.  An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. , 1999, Seminars in oncology.

[8]  Krista A. Zanetti,et al.  Molecular cloning, characterization and alternative splicing of the human cytoplasmic serine hydroxymethyltransferase gene. , 1998, Gene.

[9]  P. Hollenberg,et al.  Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine. , 1998, Carcinogenesis.

[10]  R. Moran,et al.  Transcription of the Human Folylpoly-γ-glutamate Synthetase Gene* , 1997, The Journal of Biological Chemistry.

[11]  S. Krupenko,et al.  Expression, Purification, and Properties of the Aldehyde Dehydrogenase Homologous Carboxyl-terminal Domain of Rat 10-Formyltetrahydrofolate Dehydrogenase* , 1997, The Journal of Biological Chemistry.

[12]  G. Michalopoulos,et al.  Liver Regeneration , 1997, Science.

[13]  S. Krupenko,et al.  Cysteine 707 Is Involved in the Dehydrogenase Active Site of Rat 10-Formyltetrahydrofolate Dehydrogenase (*) , 1995, The Journal of Biological Chemistry.

[14]  K. Champion,et al.  Identification of a heritable deficiency of the folate-dependent enzyme 10-formyltetrahydrofolate dehydrogenase in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Ross,et al.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications , 1994, Cancer.

[16]  M. Hentze,et al.  Enzymes as RNA-binding proteins: a role for (di)nucleotide-binding domains? , 1994, Trends in biochemical sciences.

[17]  M. Rhee,et al.  Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells. , 1992, Molecular pharmacology.

[18]  R. Mackenzie,et al.  Transcriptional regulation of murine NADP+‐dependent methylenetetrahydrofolate dehydrogenase‐cyclohydrolase‐synthetase , 1991, FEBS letters.

[19]  G. P. Beardsley,et al.  (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells. , 1991, Cancer research.

[20]  A. Tse,et al.  Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. , 1991, Biochemistry.

[21]  R. Moran,et al.  A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. , 1989, The Journal of biological chemistry.

[22]  R. Mackenzie,et al.  Formyltetrahydrofolate dehydrogenase-hydrolase from pig liver: simultaneous assay of the activities. , 1986, Biochimica et biophysica acta.

[23]  S. Benkovic,et al.  The transformylase enzymes of de novo purine biosynthesis , 1984 .

[24]  G. Weber.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. , 1983, Cancer research.

[25]  A. Clifford,et al.  Adenine, the precursor of nucleic acids in intestinal cells unable to synthesize purines de novo. , 1981, The Journal of nutrition.

[26]  A. Clifford,et al.  Metabolism of orally and intravenously administered purines in rats. , 1980, The Journal of nutrition.

[27]  M. Scrutton,et al.  Inhibitory effects of histidine and their reversal. The roles of pyruvate carboxylase and N10-formyltetrahydrofolate dehydrogenase. , 1979, The Biochemical journal.

[28]  J. Blair,et al.  Effect of an implanted Walker tumour on metabolism of folic acid in the rat. , 1978, British Journal of Cancer.

[29]  H. Krebs,et al.  The regulation of folate and methionine metabolism. , 1976, The Biochemical journal.

[30]  R. Kisliuk.  Folate Biochemistry in Relation to Antifolate Selectivity , 1999 .

[31]  David B. Krizman,et al.  The genetics of cancer—a 3D model , 1999, Nature Genetics.

[32]  S. Kaye,et al.  New antimetabolites in cancer chemotherapy and their clinical impact. , 1998, British Journal of Cancer.

[33]  D. Wilkinson.  In situ hybridization: a practical approach , 1998 .

[34]  A. Kinsella,et al.  Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. , 1997, British Journal of Cancer.

[35]  N. Bucher.  Liver regeneration then and now , 1995 .

[36]  J. Bertino,et al.  Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of Clinical Oncology.

[37]  J. C. Schmitz,et al.  Folate metabolites as modulators of antitumor drug activity. , 1993, Advances in experimental medicine and biology.

[38]  T. Tephly,et al.  The toxicity of methanol. , 1991, Life sciences.

[39]  F. Rudolph,et al.  Role of RNA as a dietary source of pyrimidines and purines in immune function. , 1990, Nutrition.

[40]  E. Stokstad,et al.  [199] 10-Formyl tetrahydrofolate: NADP oxidoreductase , 1971 .